On May 15, 2025, Telomir Pharmaceuticals, Inc. appointed Alan Weichselbaum as Chief Financial Officer, effective May 19, 2025, at an annual salary of $60,000 and potential equity options of up to 50,000 shares; he replaces Michelle Yanez, who resigned on May 16, 2025, by mutual agreement. This change is a significant restructuring event for the company.